Senicapoc and Perampanel for Newly Diagnosed Glioblastoma

NCT07284069 · tracked via the Priya Life Science Denmark tracker

Sponsor

Aarhus University Hospital

Phase

Early Phase 1

Started

2026-03-01

Last updated

2026-05-07

Condition(s) studied

Glioblastoma

Investigational drug(s) / intervention(s)

senicapoc →Perampanel →

senicapoc: Senicapoc (ICA-17043) is a selective blocker of the intermediate-conductance calcium-activated potassium channel KCa3.1.

Perampanel: Perampanel (Fycompa®) is a non-competitive AMPA-receptor antagonist approved for the treatment of focal and generalized tonic-clonic seizures.

Study summary

Glioblastoma is the most common and aggressive form of brain cancer in adults. Despite surgery, radiotherapy, and chemotherapy, most patients only live about one year after diagnosis. There is an urgent need for new and better treatments.

Recent research has shown that glioblastoma cancer cells communicate with surrounding brain cells through electrical signals that help the tumor grow and resist treatment. Two existing drugs, perampanel (used for epilepsy) and senicapoc (previously tested for blood disorders), may block these harmful signals. Laboratory studies suggest that combining these two drugs could slow tumor growth and make cancer cells more sensitive to standard therapy.

The SENIPERA trial will test whether perampanel and senicapoc, alone and in combination, are safe and well tolerated when added to standard treatment for newly diagnosed glioblastoma. The study will also measure how well these drugs reach the brain and tumor, and how they affect tumor biology.

The study has two parts:

Part A: Tests different doses of senicapoc alone to find the maximum tolerable dose.

Part B: Randomly assigns patients to receive either perampanel alone or perampanel together with senicapoc.

Participants will all receive standard therapy, including surgery, radiochemotherapy, and adjuvant chemotherapy. During surgery, small samples of tumor and fluid will be collected safely to study how the drugs act in the body and how tumor cells respond. Participants will be closely monitored for side effects and followed with regular clinical visits and MRI scans.

The trial will take place at Aarhus University Hospital, Denmark, from February 2026 to November 2028 and will enroll 27-36 adult patients. The study aims to identify safe and biologically active treatment combinations that could be tested in larger trials to improve future glioblastoma care.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age 18 years or older 2. Presumed GBM as determined by an expert multidisciplinary neuro-oncological tumor board, including participants from neurosurgery, neuro-oncology, neurology, and neuroradiology. The assessment should be based on a whole-brain MRI according to the consensus recommendations for a standardized brain tumor imaging protocol in clinical trials, not older than 4 weeks from the assessment 3. Eligibility for surgical resection and planned postoperative concomitant radiochemotherapy and adjuvant chemotherapy according to the Stupp regimen 4. Eligible for safe postponement of surgery for 14 days from enrollment 5. Life expectancy \> 3 months 6. WHO Performance Status ≤ 2. 7. Ability to provide written informed consent. 8. Use of validated anti-conception for fertile female participants in concordance with guidelines provided by the Danish health and medicines authority. 9. Signed written consent form. Exclusion Criteria: 1. Pregnancy or nursing. Fertile female participants will be required to take a validated pregnancy test for evaluation of pregnancy. 2. Previous treatment with or allergic reaction to perampanel or senicapoc. 3. Contraindications for senicapoc or perampanel treatment. 4. Previous malignancy with completion of treatment within five years before inclusion, except for basal cell carcinoma. 5. Concomitant intake of enzyme-inducing antiepileptic drugs (carbamazepine, phenytoin, phenobarbotal, or primidon). 6. Significant co-morbidities, i.e. 1. Significant liver function impairment (ALAT \> 210 umol/L for men and \> 135 umol/L for women or total bilirubin \> 25 umol/L) 2. Significant renal impairment (eGFR \< 60 mL) 3. Coagulopathy (INR \> 1.8 or APTT \> 57s) 4. Thrombocytopenia (platelet count \< 100 x 103/μL = 100 x 109/L) 5. Neutropenia (ANC \< 1.5 x 103/μL = 1.5 x 109/L) 6. Anemia (Hb \< 10 g/L = 6.0 mmol/l) 7. Severe cognitive impairment. 7. Active participation in another therapeutic interventional clinical trial. 8. Any condition that might affect the absorption, distribution, metabolism, or excretion of the trial drugs (including malabsorption states as Whipple's disease, short bowel syndrome, etc.).

Primary outcome measure(s)

Maximum tolerable dose of senicapoc monotherapy (mg) — First four weeks of treatment
The primary endpoint of the study's Part A will be the maximum tolerable dose of senicapoc monotherapy (milligrams, first four weeks) when added to standard-of-care therapy.
Number of patients in each group (2 and 3) excluded from the study due to intolerability when exposed to perampanel at the lowest dose (2 mg) — First six weeks of treatment
The primary endpoint of Part B is the number of patients in each group (2 and 3) excluded from the study due to intolerability when exposed to perampanel at the lowest dose (2 mg) within the first 6 weeks of treatment.

Trial sites (1)

Facility	City	Region	Status
Aarhus University Hospital, Department of Neurosurgery	Aarhus	Denmark	Recruiting

More Aarhus University Hospital trials in Denmark

Body Project SMIL: Prevention of Eating Disorders Among Young Women With Psychiatric Illness With the Body Project Starting soon

Assessment of Residual Congestion in Acute Decompensated Heart Failure Recruiting

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke Recruiting

Progressive Resistance Training for Adults With External Snapping Hip Recruiting

Beyond Survival: Addressing Gynecological and Sexual Health in Women After Radiotherapy for Anal Cancer Recruiting

Other trials for the same condition

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM Recruiting

Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients Recruiting

Supramarginal Resection in Glioblastoma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07284069 on ClinicalTrials.gov ↗ ← All trials in Denmark